College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top5, Ewha Womans University, Seoul 120-750, Republic of Korea.
College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
Eur J Med Chem. 2014 Jun 10;80:428-38. doi: 10.1016/j.ejmech.2014.04.066. Epub 2014 Apr 24.
We describe our rationale for designing specific catalytic inhibitors of topoisomerase II (topo II) over topoisomerase I (topo I). Based on 3D-QSAR studies of previously published dihydroxylated 2,4-diphenyl-6-aryl pyridine derivatives, 9 novel dihydroxylated 2,4-diphenyl-6-thiophen-2-yl pyridine compounds were designed, synthesized, and their biological activities were evaluated. These compounds have 2-thienyl ring substituted on the R(3) group on the pyridine ring and they all showed excellent specificity toward topo II compared to topo I. In vitro experiments were performed for compound 13 to determine the mechanism of action for this series of compounds. Compound 13 inhibited topoisomerase II specifically by non-intercalative binding to DNA and did not stabilize enzyme-cleavable DNA complex. Compound 13 efficiently inhibited cell viability, cell migration, and induced G1 arrest. Also from 3D-QSAR studies, the results were compared with other previously published dihydroxylated 2,4-diphenyl-6-aryl pyridine derivatives to explain the structure-activity relationships.
我们描述了设计拓扑异构酶 II(topo II)特异性催化抑制剂而非拓扑异构酶 I(topo I)的原理。基于先前发表的二羟基化 2,4-二苯基-6-芳基吡啶衍生物的 3D-QSAR 研究,设计并合成了 9 种新型二羟基化 2,4-二苯基-6-噻吩-2-基吡啶化合物,并评估了它们的生物学活性。这些化合物在吡啶环的 R(3)基团上具有噻吩基环取代,与 topo I 相比,它们对 topo II 均表现出优异的特异性。为了确定这一系列化合物的作用机制,对化合物 13 进行了体外实验。化合物 13 通过非嵌入方式与 DNA 特异性结合来抑制拓扑异构酶 II,而不会稳定酶可切割的 DNA 复合物。化合物 13 有效地抑制了细胞活力、细胞迁移,并诱导 G1 期阻滞。此外,通过 3D-QSAR 研究,还将结果与其他先前发表的二羟基化 2,4-二苯基-6-芳基吡啶衍生物进行了比较,以解释结构-活性关系。